Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

Osugacestat (AL101, BMS-906024)

ACCURACY

Ayala Pharmaceuticals · Phase 2 · Completed · Enrollment 87

NCT03691207

ArmReported safety
AL101 4 mgpatients with serious adverse events: 23 patients (of 45), final
AL101 6 mgpatients with serious adverse events: 26 patients (of 42), final

A count stays a count. This page does not turn a count into a percent.